11/21
06:30 am
blrx
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
High
Report
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
11/20
07:19 am
blrx
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
Medium
Report
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
11/16
03:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
11/6
08:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.
11/5
09:00 am
blrx
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
Low
Report
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
10/31
02:04 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Low
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/23
02:06 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
10/16
09:18 am
blrx
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide [Seeking Alpha]
Medium
Report
BioLineRx receives USPTO allowance of new composition of matter patent on motixafortide [Seeking Alpha]
10/16
07:00 am
blrx
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
High
Report
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
10/15
02:07 am
blrx
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
Medium
Report
BioLineRx Ltd. (NASDAQ: BLRX) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.
9/17
01:14 pm
blrx
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection [Yahoo! Finance]
Low
Report
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection [Yahoo! Finance]
9/17
01:01 pm
blrx
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection
Low
Report
BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection